SFM
COGT icon

Sphera Funds Management’s Cogent Biosciences COGT Stock Holding History

Sphera Funds Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$1.44M – 118
2025
Q2 		$1.44M Buy
+200,000
New +$1.11M 0.34% 76

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sphera Funds Management's COGT Position: Q2 2026 in Review

Sphera Funds Management increased its Cogent Biosciences (COGT) stake by 10% in Q2 2026, buying an estimated $1.5M and bringing the position to 459,340 shares worth $17.8M. The position accounts for 2.32% of the portfolio, ranked #12.

Sphera Funds Management first reported a position in COGT in Q4 2020 and has held it in 12 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Sphera Funds Management held 459,340 shares of Cogent Biosciences worth $17.8M as of Q2 2026.
  • Sphera Funds Management bought 43,000 Cogent Biosciences shares in Q2 2026, an estimated $1.5M.
  • Cogent Biosciences made up 2.32% of Sphera Funds Management's portfolio in Q2 2026, its #12 holding.
  • Sphera Funds Management first reported a position in Cogent Biosciences in Q4 2020 and has held it in 12 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.